DEADLINE ALARM for MNSO, AMPE and LTRY: The Law Offices of

LOS ANGELES, Oct. 05, 2022 (GLOBE NEWSWIRE) — The law office of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders in the following public companies. Investors have until the deadlines set out below to file a lead plaintiff filing.

Investors who experience losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email at [email protected].

MINISO Group Holding Limited (NYSE: MNSO)
Class Period: October 12, 2020 – August 17, 2022
Deadline for lead plaintiff: October 17, 2022

The complaint filed in this class action alleges that the defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations and prospects. Specifically, Defendants failed to disclose to investors that: (1) Defendants and other undisclosed related parties owned and controlled a much larger number of MINISO stores than previously disclosed; (2) as a result, MINISO concealed its true costs; (3) the company has not presented its true business model; (4) defendants, including the Company and its CEO, were involved in proposed unusual and unclear transactions; (5) as a result of at least one of these transactions, the Company is at risk of breaching contracts with PRC authorities; (6) the company would immediately and drastically reduce its franchise fees; and (7) as a result, the defendants’ positive statements about the Company’s business, operations and prospects were materially misleading and/or lacking a reasonable basis at all relevant times.

If you are a MINISO shareholder who has suffered a loss, click here take part.

Ampio Pharmaceuticals, Inc. (NYSE: AMPE)
Class Period: December 29, 2020 – August 3, 2022
Deadline for lead plaintiff: October 17, 2022

The complaint filed in this class action lawsuit alleges that throughout the…

Continue to read on GlobeNewswire